Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000236690 | SCV000292934 | uncertain significance | not provided | 2023-08-18 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with endometrial cancer in published literature (Scott et al., 2022); Published functional studies suggest this variant has no damaging effect based on results of an assay measuring resistance to 6-TG (Jia et al., 2020); This variant is associated with the following publications: (PMID: 18822302, 21120944, 33357406, 36550560) |
Labcorp Genetics |
RCV000456430 | SCV000548173 | benign | Hereditary nonpolyposis colorectal neoplasms | 2024-12-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000563882 | SCV000664843 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-06-14 | criteria provided, single submitter | clinical testing | The p.S297R variant (also known as c.891C>G), located in coding exon 5 of the MSH2 gene, results from a C to G substitution at nucleotide position 891. The serine at codon 297 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000236690 | SCV000889444 | uncertain significance | not provided | 2018-03-27 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000563882 | SCV000908284 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-06-12 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003463695 | SCV004196243 | uncertain significance | Lynch syndrome 1 | 2023-09-20 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004806269 | SCV005429069 | uncertain significance | Lynch syndrome | 2024-07-29 | criteria provided, single submitter | clinical testing | This missense variant replaces serine with arginine at codon 297 of the MSH2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). This variant does not impact MSH2 function in a 6-thioguanine sensitivity assay in haploid human cells (internally defined LOF score threshold <= -1.32, PMID: 33357406). This variant has been reported in an individual affected with uterine and/or endometrial cancer (PMID: 36550560). This variant has been identified in 3/279824 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |